Valens Int. d.o.o., Slovenija   Report issue

For profit Phase 1 Phase 2
Founded: Sencur Slovenia (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2007
NCT00500929
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Cardiometabolics | MEDEDUS, Ljubljana, Slovenia | Valens Int. d.o.o., Slovenija

Active Ingredients

Drugs in Phase 2 Trials (1)

sodium dichloroacetate (1 trial)

Drugs in Phase 1 Trials (1)

ubiquinone (3 trials)

Drugs in Other Trials (4)

beta-glucans (1 trial)

collagen (1 trial)

lutein (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6